Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor
作者： Frank Sommer
关键词: Pharmacotherapy 、 In vitro 、 Pharmacology 、 In vivo 、 Erectile dysfunction 、 Internal medicine 、 Endocrinology 、 Adverse effect 、 Medicine 、 cGMP-specific phosphodiesterase type 5 、 Vardenafil 、 Potency
摘要: Erectile dysfunction (ED) is a widespread, age-related medical condition that affects > 50% of men aged 40 – 70 years. Pharmacotherapy with orally available phosphodiesterase 5 (PDE5) inhibitors offers convenient and simple approach to treatment. Results numerous clinical trials have demonstrated significant efficacy in restoring the ability achieve sustain an erection, adverse side effects are generally mild-to-moderate severity. Vardenafil highly selective, potent PDE5 inhibitor developed for treatment ED. The potency selectivity vardenafil other PDE isoforms been evaluated vitro vivo compared compounds class. This review will discuss findings biochemical, experiments indicate superior high vardenafil.
informahealthcare.com参考文章(41)
Arnold Melman, Alexandru E. Benet, The epidemiology of erectile dysfunction. Urologic Clinics of North America. ,vol. 22, pp. 699- 709 ,(1995) , 10.1016/S0094-0143(21)00690-X
C H Gleiter, Ursula Gresser, Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature European Journal of Medical Research. ,vol. 7, pp. 435- 446 ,(2002)
Arthur L. Burnett, Erectile dysfunction: a practical approach for primary care. Geriatrics. ,vol. 53, pp. 34- 48 ,(1998)
Thomas Segerson, Terry Taylor, Marc Thibonnier, Harin Padma‐Nathan, Wayne J. G. Hellstrom, Gary Karlin, Marc Gittelman, Vardenafil for Treatment of Men With Erectile Dysfunction: Efficacy and Safety in a Randomized, Double-Blind, Placebo-Controlled Trial Journal of Andrology. ,vol. 23, pp. 763- 771 ,(2002) , 10.1002/J.1939-4640.2002.TB02332.X
Luke O'Connell, Abdulmaged M Traish, Abdulmaged M Traish, Seong Choi, Ricardo Munarriz, Erwin Bischoff, Noel N Kim, Irwin Goldstein, Kweonsik Min, Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. Journal of Andrology. ,vol. 23, pp. 332- 337 ,(2002) , 10.1002/J.1939-4640.2002.TB02239.X
Aversa A, Fabbri A, Caprio M, Pathology of erection. Journal of Endocrinological Investigation. ,vol. 26, pp. 87- 90 ,(2003)
Aytaç, Mckinlay, Krane, The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences BJUI. ,vol. 84, pp. 50- 56 ,(1999) , 10.1046/J.1464-410X.1999.00142.X
Melvin D. Cheitlin, Adolph M. Hutter, Ralph G. Brindis, Peter Ganz, Sanjay Kaul, Richard O. Russell, Randall M. Zusman, James S. Forrester, Pamela S. Douglas, David P. Faxon, John D. Fisher, Raymond J. Gibbons, Jonathan L. Halperin, Adolph M. Hutter, Judith S. Hochman, Sanjiv Kaul, William S. Weintraub, William L. Winters, Michael J. Wolk, Use of sildenafil (Viagra) in patients with cardiovascular disease Journal of the American College of Cardiology. ,vol. 33, pp. 273- 282 ,(1999) , 10.1016/S0735-1097(98)00656-1
I Saenz de Tejada, J Angulo, P Cuevas, A Fernández, I Moncada, A Allona, E Lledó, HG Körschen, U Niewöhner, H Haning, E Pages, E Bischoff, The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil International Journal of Impotence Research. ,vol. 13, pp. 282- 290 ,(2001) , 10.1038/SJ.IJIR.3900726
Sharron H. Francis, Jackie D. Corbin, Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. Current Urology Reports. ,vol. 4, pp. 457- 465 ,(2003) , 10.1007/S11934-003-0027-X